{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T03:28:18Z","timestamp":1775791698064,"version":"3.50.1"},"reference-count":92,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1053\/j.ajkd.2015.01.030","type":"journal-article","created":{"date-parts":[[2015,5,7]],"date-time":"2015-05-07T17:48:21Z","timestamp":1431020901000},"page":"564-576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Total Kidney Volume in Autosomal Dominant Polycystic Kidney\u00a0Disease: A Biomarker of Disease Progression and Therapeutic Efficacy"],"prefix":"10.1053","volume":"66","author":[{"given":"Ahsan","family":"Alam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neera K.","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua H.","family":"Lipschutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Sapir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"McFarlane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel G.","family":"Bichet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9569","key":"10.1053\/j.ajkd.2015.01.030_bib1","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"10.1053\/j.ajkd.2015.01.030_bib2","first-page":"393","article-title":"Developments in the management of autosomal dominant polycystic kidney disease","volume":"4","author":"Masoumi","year":"2008","journal-title":"Ther Clin Risk Manag"},{"issue":"1 suppl 1","key":"10.1053\/j.ajkd.2015.01.030_bib3","first-page":"e1","article-title":"US Renal Data System 2012 annual data report","volume":"61","author":"Collins","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1053\/j.ajkd.2015.01.030_bib4","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2215\/CJN.00780110","article-title":"Renal function and healthcare costs in patients with polycystic kidney disease","volume":"5","author":"Lentine","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2015.01.030_bib5","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1681\/ASN.2007060665","article-title":"Src inhibition ameliorates polycystic kidney disease","volume":"19","author":"Sweeney","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"50","key":"10.1053\/j.ajkd.2015.01.030_bib6","doi-asserted-by":"crossref","first-page":"38818","DOI":"10.1074\/jbc.M110.145284","article-title":"MAP\/ERK kinase kinase 1 (MEKK1) mediates transcriptional repression by interacting with polycystic kidney disease-1 (PKD1) promoter-bound p53 tumor suppressor protein","volume":"285","author":"Islam","year":"2010","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"10.1053\/j.ajkd.2015.01.030_bib7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.transproceed.2013.10.040","article-title":"Sirolimus for treatment of autosomal-dominant polycystic kidney disease: a meta-analysis of randomized controlled trials","volume":"46","author":"Liu","year":"2014","journal-title":"Transplant Proc"},{"issue":"7","key":"10.1053\/j.ajkd.2015.01.030_bib8","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1681\/ASN.2008090927","article-title":"Calcimimetic inhibits late-stage cyst growth in ADPKD","volume":"20","author":"Gattone","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2015.01.030_bib9","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1093\/ndt\/gfp777","article-title":"Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model of ADPKD","volume":"25","author":"Leuenroth","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"9903","key":"10.1053\/j.ajkd.2015.01.030_bib10","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of long-acting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"issue":"25","key":"10.1053\/j.ajkd.2015.01.030_bib11","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1053\/j.ajkd.2015.01.030_bib12","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nrneph.2011.109","article-title":"Why kidneys fail in autosomal dominant polycystic kidney disease","volume":"7","author":"Grantham","year":"2011","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2015.01.030_bib13","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1523-1755.2003.00185.x","article-title":"Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort","volume":"64","author":"Chapman","year":"2003","journal-title":"Kidney Int"},{"issue":"20","key":"10.1053\/j.ajkd.2015.01.030_bib14","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2015.01.030_bib15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2215\/CJN.00330705","article-title":"Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes","volume":"1","author":"Grantham","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2015.01.030_bib16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2015.01.030_bib17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.semnephrol.2011.05.003","article-title":"Imaging approaches to patients with polycystic kidney disease","volume":"31","author":"Chapman","year":"2011","journal-title":"Semin Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2015.01.030_bib18","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.semnephrol.2010.06.002","article-title":"Diagnosis of autosomal-dominant polycystic kidney disease: an integrated approach","volume":"30","author":"Barua","year":"2010","journal-title":"Semin Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2015.01.030_bib19","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/j.1523-1755.2005.00201.x","article-title":"Molecular pathogenesis of ADPKD: the polycystin complex gets complex","volume":"67","author":"Ong","year":"2005","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2015.01.030_bib20","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1681\/ASN.2006111215","article-title":"Role of primary cilia in the pathogenesis of polycystic kidney disease","volume":"18","author":"Yoder","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2015.01.030_bib21","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/MNH.0b013e3283621510","article-title":"Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease","volume":"22","author":"Devuyst","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"10","key":"10.1053\/j.ajkd.2015.01.030_bib22","first-page":"1291","article-title":"Cyclic AMP-mediated cyst expansion","volume":"1812","author":"Wallace","year":"2011","journal-title":"Biochem Biophys Acta"},{"issue":"10","key":"10.1053\/j.ajkd.2015.01.030_bib23","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"issue":"2","key":"10.1053\/j.ajkd.2015.01.030_bib24","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.ackd.2010.01.006","article-title":"Treatment strategies and clinical trial design in ADPKD","volume":"17","author":"Torres","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2015.01.030_bib25","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2215\/CJN.00060108","article-title":"Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies","volume":"3","author":"Chapman","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"21","key":"10.1053\/j.ajkd.2015.01.030_bib26","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.4161\/cc.5.21.3408","article-title":"Regulation of mTOR by polycystin-1: is polycystic kidney disease a case of futile repair?","volume":"5","author":"Weimbs","year":"2006","journal-title":"Cell Cycle"},{"key":"10.1053\/j.ajkd.2015.01.030_bib27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2369-8-12","article-title":"p21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levels","volume":"8","author":"Park","year":"2007","journal-title":"BMC Nephrol"},{"issue":"8497","key":"10.1053\/j.ajkd.2015.01.030_bib28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0140-6736(86)92557-2","article-title":"Prenatal diagnosis of autosomal dominant polycystic kidney disease with a DNA probe","volume":"2","author":"Reeders","year":"1986","journal-title":"Lancet"},{"issue":"10","key":"10.1053\/j.ajkd.2015.01.030_bib29","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1097\/01.ASN.0000088720.61783.19","article-title":"Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease","volume":"14","author":"Zheng","year":"2003","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2015.01.030_bib30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1476-9255-7-19","article-title":"Role of inflammation in tubulo-interstitial damage associated to obstructive nephropathy","volume":"7","author":"Grande","year":"2010","journal-title":"J\u00a0Inflamm (Lond)"},{"issue":"5","key":"10.1053\/j.ajkd.2015.01.030_bib31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/nep.12045","article-title":"Role of interstitial inflammation in the pathogenesis of polycystic kidney disease","volume":"18","author":"Ta","year":"2013","journal-title":"Nephrology (Carlton)"},{"issue":"10","key":"10.1053\/j.ajkd.2015.01.030_bib32","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.2215\/CJN.01010211","article-title":"Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease","volume":"6","author":"Helal","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2015.01.030_bib33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000341263","article-title":"Emergent early markers of renal progression in autosomal-dominant polycystic kidney disease patients: implications for prevention and treatment","volume":"36","author":"Helal","year":"2012","journal-title":"Am J Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2015.01.030_bib34","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1681\/ASN.2007020155","article-title":"Autosomal dominant polycystic kidney disease: time for a change?","volume":"18","author":"Chapman","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2015.01.030_bib35","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nrneph.2009.214","article-title":"Imaging for the prognosis of autosomal dominant polycystic kidney disease","volume":"6","author":"Bae","year":"2010","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2015.01.030_bib36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nrneph.2009.75","article-title":"The cadence of kidney growth in ADPKD","volume":"5","author":"Chapman","year":"2009","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2015.01.030_bib37","doi-asserted-by":"crossref","first-page":"820","DOI":"10.2215\/CJN.02810608","article-title":"Prospective change in renal volume and function in children with ADPKD","volume":"4","author":"Cadnapaphornchai","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2015.01.030_bib38","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1 mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le Gall","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2015.01.030_bib39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2215\/CJN.00930306","article-title":"Normal values for renal length and volume as measured by magnetic resonance imaging","volume":"2","author":"Cheong","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2015.01.030_bib40","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000355375","article-title":"Novel approach to estimate kidney and cyst volumes using mid-slice magnetic resonance images in polycystic kidney disease","volume":"38","author":"Bae","year":"2013","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2015.01.030_bib41","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1053\/j.ajkd.2011.02.392","article-title":"Noninvasive and direct measures of kidney size in kidney donors","volume":"58","author":"Hwang","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2015.01.030_bib42","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classi\ufb01cation of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2015.01.030_bib43","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1053\/j.ajkd.2005.08.026","article-title":"Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP)","volume":"46","author":"O'Neill","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2015.01.030_bib44","first-page":"686A","volume":"24","author":"Chapman","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2015.01.030_bib45","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.repbio.2013.11.002","article-title":"3D ultrasound imaging of the human corpus luteum","volume":"14","author":"Brezinka","year":"2014","journal-title":"Reprod Biol"},{"issue":"2","key":"10.1053\/j.ajkd.2015.01.030_bib46","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3348\/kjr.2014.15.2.226","article-title":"Differentiating between adenomyomatosis and gallbladder cancer: revisiting a comparative study of high-resolution ultrasound, multidetector CT, and MR imaging","volume":"15","author":"Bang","year":"2014","journal-title":"Korean J Radiol"},{"key":"10.1053\/j.ajkd.2015.01.030_bib47","doi-asserted-by":"crossref","first-page":"687A","DOI":"10.1681\/ASN.2013030294","volume":"24","author":"Rahbari-Oskoui","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2015.01.030_bib48","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1046\/j.1523-1755.2001.00985.x","article-title":"Pain management in polycystic kidney disease","volume":"60","author":"Bajwa","year":"2001","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2015.01.030_bib49","first-page":"1","article-title":"Interpretation of renal volume in autosomal dominant polycystic kidney disease and relevant clinical implications","volume":"5","author":"Masoumi","year":"2011","journal-title":"Iran J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2015.01.030_bib50","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1111\/j.1523-1755.2004.00921.x","article-title":"Pain patterns in patients with polycystic kidney disease","volume":"66","author":"Bajwa","year":"2004","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2015.01.030_bib51","first-page":"222","article-title":"Autosomal dominant polycystic kidney disease and pain\u2014a review of the disease from aetiology, evaluation, past surgical treatment options to current practice","volume":"50","author":"Badani","year":"2004","journal-title":"J\u00a0Postgrad Med"},{"issue":"2","key":"10.1053\/j.ajkd.2015.01.030_bib52","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1053\/j.ajkd.2013.08.017","article-title":"Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study","volume":"63","author":"Miskulin","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2015.01.030_bib53","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1590\/S0100-879X2006000400014","article-title":"Renal and extrarenal manifestations of autosomal polycystic kidney disease","volume":"39","author":"Rom\u00e3o","year":"2006","journal-title":"Braz J Med Biol Res"},{"issue":"2","key":"10.1053\/j.ajkd.2015.01.030_bib54","first-page":"160","article-title":"Medical therapy with tranexamic acid in autosomal dominant polycystic kidney disease patients with severe haematuria","volume":"32","author":"Peces","year":"2012","journal-title":"Nefrologia"},{"issue":"11","key":"10.1053\/j.ajkd.2015.01.030_bib55","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1681\/ASN.2013111184","article-title":"Predictors of autosomal dominant polycystic kidney disease progression","volume":"25","author":"Schrier","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2015.01.030_bib56","first-page":"161","article-title":"The influence of renal manifestations to the progression of autosomal dominant polycystic kidney disease","volume":"13","author":"Idrizi","year":"2009","journal-title":"Hippokratia"},{"issue":"2","key":"10.1053\/j.ajkd.2015.01.030_bib57","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00240-005-0019-z","article-title":"Lithiasis in cystic kidney disease and malformations of the urinary tract","volume":"34","author":"Gambaro","year":"2006","journal-title":"Urol Res"},{"issue":"3","key":"10.1053\/j.ajkd.2015.01.030_bib58","doi-asserted-by":"crossref","first-page":"c270","DOI":"10.1159\/000320745","article-title":"Demographic and clinical characteristics of patients with autosomal dominant polycystic kidney disease: a multicenter experience","volume":"117","author":"Kazancioglu","year":"2011","journal-title":"Nephron Clin Pract"},{"issue":"4","key":"10.1053\/j.ajkd.2015.01.030_bib59","doi-asserted-by":"crossref","first-page":"838","DOI":"10.2215\/CJN.03100608","article-title":"Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients","volume":"4","author":"Nishiura","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2015.01.030_bib60","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1053\/j.ackd.2010.01.001","article-title":"Hypertension in autosomal dominant polycystic kidney disease","volume":"17","author":"Chapman","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2015.01.030_bib61","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nrneph.2009.13","article-title":"Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease","volume":"5","author":"Ecder","year":"2009","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2015.01.030_bib62","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/01.hjh.0000222765.30348.0d","article-title":"The effect of sodium and angiotensin-converting enzyme inhibition on the classic circulating renin-angiotensin system in autosomal-dominant polycystic kidney disease patients","volume":"24","author":"Doulton","year":"2006","journal-title":"J\u00a0Hypertens"},{"issue":"11, pt 1","key":"10.1053\/j.ajkd.2015.01.030_bib63","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.amjhyper.2004.06.020","article-title":"Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U.S. population","volume":"17","author":"Kelleher","year":"2004","journal-title":"Am J Hypertens"},{"issue":"9","key":"10.1053\/j.ajkd.2015.01.030_bib64","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1681\/ASN.2008080882","article-title":"Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease","volume":"20","author":"Schrier","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2015.01.030_bib65","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/ki.2008.397","article-title":"Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension","volume":"74","author":"Cadnapaphornchai","year":"2008","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2015.01.030_bib66","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/ki.2011.411","article-title":"Analysis of baseline parameters in the HALT polycystic kidney disease trials","volume":"81","author":"Torres","year":"2012","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2015.01.030_bib67","first-page":"61A","article-title":"Effect of tolvaptan on urine osmolality versus outcome in ADPKD: results from the TEMPO 3:4 trial. Presented at: Kidney Week 2013; November 5-10, 2013; Atlanta, GA","volume":"24","author":"Devuyst","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2015.01.030_bib68","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1053\/ajkd.2002.33379","article-title":"Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study","volume":"39","author":"Fick-Brosnahan","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2015.01.030_bib69","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF02927815","article-title":"Volume of polycystic kidneys during reduction of renal function","volume":"3","author":"Thomsen","year":"1981","journal-title":"Urol Radiol"},{"issue":"8","key":"10.1053\/j.ajkd.2015.01.030_bib70","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1681\/ASN.V1181505","article-title":"Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease","volume":"11","author":"King","year":"2000","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2015.01.030_bib71","doi-asserted-by":"crossref","first-page":"c173","DOI":"10.1159\/000092915","article-title":"Reliability of magnetic resonance imaging for measuring the volumetric indices in autosomal-dominant polycystic kidney disease: correlation with hypertension and renal function","volume":"103","author":"Lee","year":"2006","journal-title":"Nephron Clin Pract"},{"issue":"3","key":"10.1053\/j.ajkd.2015.01.030_bib72","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ki.2011.119","article-title":"Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease","volume":"80","author":"Irazabal","year":"2011","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2015.01.030_bib73","first-page":"687A","article-title":"Correlation of total kidney volume and eGFR in patients with ADPKD: results from the TEMPO 3:4 trial. Presented at Kidney Week 2013; November 5-10, 2013; Atlanta, GA","volume":"24","author":"Perrone","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2015.01.030_bib74","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1046\/j.1523-1755.2000.00433.x","article-title":"Volumetric determination of progression in autosomal dominant polycystic kidney disease by computed tomography","volume":"58","author":"Sise","year":"2000","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2015.01.030_bib75","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1681\/ASN.2005070697","article-title":"Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the Consortium of Radiologic Imaging Studies of Polycystic Kidney Disease cohort","volume":"17","author":"Rule","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2015.01.030_bib76","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2215\/CJN.00910306","article-title":"Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease","volume":"2","author":"Torres","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2015.01.030_bib77","doi-asserted-by":"crossref","first-page":"640","DOI":"10.2215\/CJN.03250410","article-title":"Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease","volume":"6","author":"Torres","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2015.01.030_bib78","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000254338","article-title":"Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy","volume":"32","author":"Wuthrich","year":"2009","journal-title":"Kidney Blood Press Res"},{"issue":"6","key":"10.1053\/j.ajkd.2015.01.030_bib79","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1681\/ASN.2009121302","article-title":"Sirolimus therapy to halt the progression of ADPKD","volume":"21","author":"Perico","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2015.01.030_bib80","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1053\/j.ajkd.2015.01.030_bib81","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1053\/j.ajkd.2015.01.030_bib82","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1093\/ndt\/gfs264","article-title":"Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study","volume":"27","author":"Stallone","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1053\/j.ajkd.2015.01.030_bib83","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1016\/j.transproceed.2009.05.032","article-title":"Sirolimus therapy for patients with adult polycystic kidney disease: a pilot study","volume":"41","author":"Soliman","year":"2009","journal-title":"Transplant Proc"},{"issue":"10","key":"10.1053\/j.ajkd.2015.01.030_bib84","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1016\/j.transproceed.2012.06.073","article-title":"Sirolimus produced S-shaped effect on adult polycystic kidneys after 2-year treatment","volume":"44","author":"Soliman","year":"2012","journal-title":"Transplant Proc"},{"issue":"5","key":"10.1053\/j.ajkd.2015.01.030_bib85","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2215\/CJN.02650313","article-title":"Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study","volume":"9","author":"Braun","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2015.01.030_bib86","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease","volume":"68","author":"Ruggenenti","year":"2005","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2015.01.030_bib87","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"Hogan","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2015.01.030_bib88","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1093\/ndt\/gfs152","article-title":"Somatostatin analog therapy for severe polycystic liver disease: results after\u00a02 years","volume":"27","author":"Hogan","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.ajkd.2015.01.030_bib89","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2215\/CJN.08350813","article-title":"Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease","volume":"9","author":"Cadnapaphornchai","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"24","key":"10.1053\/j.ajkd.2015.01.030_bib90","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2015.01.030_bib91","doi-asserted-by":"crossref","first-page":"831","DOI":"10.2215\/CJN.02480314","article-title":"Novel treatments of autosomal dominant polycystic kidney disease","volume":"9","author":"Mahnensmith","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2015.01.030_bib92","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1056\/NEJMe1006925","article-title":"mTOR inhbitors in polycystic kidney disease","volume":"363","author":"Watnick","year":"2010","journal-title":"N\u00a0Engl J Med"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638615005247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638615005247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:39:28Z","timestamp":1759459168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638615005247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":92,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0272638615005247"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2015.01.030","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Total Kidney Volume in Autosomal Dominant Polycystic Kidney\u00a0Disease: A Biomarker of Disease Progression and Therapeutic Efficacy","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2015.01.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}